OpenEvidence, a Miami-based AI platform designed to assist physicians with clinical decisions, is reportedly seeking to raise $200 million at a staggering $20 billion valuation. This valuation represents nearly a sixfold increase from the company's $3.5 billion worth just a year ago, and a sharp rise from $12 billion reached only months prior. Such explosive growth shows a broader trend in venture capital, where AI-driven healthcare solutions are rapidly capturing investor attention and capital.
The fundraising velocity is remarkable: OpenEvidence has secured around $700 million in a series of rounds over the past twelve months. Back in October 2025, its Series C round brought in $200 million at a $6 billion valuation, followed three months later by a $250 million Series D that doubled that valuation to $12 billion. The group of investors backing this company reads like a tech hall of fame, including Thrive Capital, DST Global, Sequoia, Google Ventures, Nvidia, and the Mayo Clinic, highlighting both Silicon Valley’s and traditional healthcare’s vested interest in AI.
OpenEvidence offers clinical decision support by leveraging AI trained on trusted medical literature such as the New England Journal of Medicine and oncology guidelines from the NCCN. Its user base is significant: over 40% of US doctors across more than 10,000 hospitals reportedly rely on the platform. Despite having reported annual revenue of approximately $150 million, the company’s valuation implies a revenue multiple exceeding 130 times, an indicator of immense investor confidence but also a signal that expectations for future growth and market penetration are extraordinarily high. The requirement that all users be verified healthcare professionals both builds trust and acts as a natural barrier to rapid user expansion.
This case sheds light on how venture capital is channeling funds into AI solutions with tangible healthcare applications rather than speculative technologies like blockchain or crypto. Given that US healthcare spending runs into the trillions annually, platforms like OpenEvidence represent gateways to tapping into a colossal market through AI-enabled efficiencies and improved clinical outcomes.
What remains to be seen is if the company will close the $200 million raise at or above this $20 billion valuation, which would place OpenEvidence among the most valuable private AI companies worldwide. Such a milestone would not only validate the AI healthcare sector's breakneck growth but also provide a benchmark for future investments in this space.
This material is for informational purposes only and does not constitute financial advice.
